TMC Life Sciences Berhad announced redesignation of Dr Heng Jun Li Melvin from previous position Non Executive Director to new position Group Chief Executive Officer, Directorate is Executive. Age is 41, gender is Male and nationality is Singapore. Date of change is 29 January 2024. Qualifications: Masters of Business Administration from Frankfurt School of Finance & Management; Bachelor of Medicine and Bachelor of Surgery (MBBS) from University of London, St Georges Hospital; Graduate Diploma Occupational Medicine from National University of Singapore. Working experience and occupation: Thomson Medical Group Limited, Singapore 1 December 2022 to present Executive Director and Group Chief Executive Officer; Gleneagles Hospital, IHH Healthcare January 2021 to 31 October 2022 Chief Executive Officer; July 2019 to December 2020 Chief Operating Officer September 2017 to June 2019 AVP, Operations; Mesh Bio Pte Ltd. July 2018 to Present Co-Founder & Medical Advisor; Ministry of Health, Singapore August 2016 to January 2018 Medical Advisor; Global Health Byte Holdings Pte Ltd. (UNO Technologies Pte Ltd) June 2016 to December 2018 Investor & Medical Advisor; OneCare Medical Pte Ltd. August 2014 to September 2017 Equity Partner; Global Medical Concierge Pte Ltd.
January 2013 to June 2017 Co-Founder; Tan Tock Seng Hospital January 2013 to March 2015 Medical Doctor, Radiology; National Health Service (United Kingdom) June 2009 to August 2011 Medical Doctor. Dr Heng Jun Li Melvin will assume the role of Acting Group Chief Executive Officer of the Company on 29 January 2024.